407 related articles for article (PubMed ID: 32717806)
1. Perspectives for New and More Efficient Multifunctional Ligands for Alzheimer's Disease Therapy.
Zagórska A; Jaromin A
Molecules; 2020 Jul; 25(15):. PubMed ID: 32717806
[TBL] [Abstract][Full Text] [Related]
2. Navigating the Chemical Space of Multitarget-Directed Ligands: From Hybrids to Fragments in Alzheimer's Disease.
Prati F; Cavalli A; Bolognesi ML
Molecules; 2016 Apr; 21(4):466. PubMed ID: 27070562
[TBL] [Abstract][Full Text] [Related]
3. Multi-target design strategies for the improved treatment of Alzheimer's disease.
Zhang P; Xu S; Zhu Z; Xu J
Eur J Med Chem; 2019 Aug; 176():228-247. PubMed ID: 31103902
[TBL] [Abstract][Full Text] [Related]
4. A physicochemical descriptor based method for effective and rapid screening of dual inhibitors against BACE-1 and GSK-3β as targets for Alzheimer's disease.
Kumar A; Srivastava G; Sharma A
Comput Biol Chem; 2017 Dec; 71():1-9. PubMed ID: 28950235
[TBL] [Abstract][Full Text] [Related]
5. Development and Application of a Virtual Screening Protocol for the Identification of Multitarget Fragments.
Bottegoni G; Veronesi M; Bisignano P; Kacker P; Favia AD; Cavalli A
ChemMedChem; 2016 Jun; 11(12):1259-63. PubMed ID: 26663255
[TBL] [Abstract][Full Text] [Related]
6. Dual BACE-1/GSK-3β Inhibitors to Combat Alzheimer's Disease: A Focused Review.
Rampa A; Gobbi S; Concetta Di Martino RM; Belluti F; Bisi A
Curr Top Med Chem; 2017; 17(31):3361-3369. PubMed ID: 29332582
[TBL] [Abstract][Full Text] [Related]
7. Searching for the Multi-Target-Directed Ligands against Alzheimer's disease: discovery of quinoxaline-based hybrid compounds with AChE, H₃R and BACE 1 inhibitory activities.
Huang W; Tang L; Shi Y; Huang S; Xu L; Sheng R; Wu P; Li J; Zhou N; Hu Y
Bioorg Med Chem; 2011 Dec; 19(23):7158-67. PubMed ID: 22019465
[TBL] [Abstract][Full Text] [Related]
8. Dual-target compounds for Alzheimer's disease: Natural and synthetic AChE and BACE-1 dual-inhibitors and their structure-activity relationship (SAR).
Ferreira JPS; Albuquerque HMT; Cardoso SM; Silva AMS; Silva VLM
Eur J Med Chem; 2021 Oct; 221():113492. PubMed ID: 33984802
[TBL] [Abstract][Full Text] [Related]
9. A review on flavonoid-based scaffolds as multi-target-directed ligands (MTDLs) for Alzheimer's disease.
Jalili-Baleh L; Babaei E; Abdpour S; Nasir Abbas Bukhari S; Foroumadi A; Ramazani A; Sharifzadeh M; Abdollahi M; Khoobi M
Eur J Med Chem; 2018 May; 152():570-589. PubMed ID: 29763806
[TBL] [Abstract][Full Text] [Related]
10. New flavonoid -
Estrada-Valencia M; Herrera-Arozamena C; Pérez C; Viña D; Morales-García JA; Pérez-Castillo A; Ramos E; Romero A; Laurini E; Pricl S; Rodríguez-Franco MI
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):712-727. PubMed ID: 31852270
[TBL] [Abstract][Full Text] [Related]
11. Biaryl scaffold-focused virtual screening for anti-aggregatory and neuroprotective effects in Alzheimer's disease.
Khalid S; Zahid MA; Ali H; Kim YS; Khan S
BMC Neurosci; 2018 Nov; 19(1):74. PubMed ID: 30424732
[TBL] [Abstract][Full Text] [Related]
12. From Kinase Inhibitors to Multitarget Ligands as Powerful Drug Leads for Alzheimer's Disease using Protein-Templated Synthesis.
Nozal V; García-Rubia A; Cuevas EP; Pérez C; Tosat-Bitrián C; Bartolomé F; Carro E; Ramírez D; Palomo V; Martínez A
Angew Chem Int Ed Engl; 2021 Aug; 60(35):19344-19354. PubMed ID: 34169618
[TBL] [Abstract][Full Text] [Related]
13. Recent Developments in Tacrine-based Hybrids as a Therapeutic Option for Alzheimer's Disease.
Yamali C; Donmez S
Mini Rev Med Chem; 2023; 23(7):869-880. PubMed ID: 36464869
[TBL] [Abstract][Full Text] [Related]
14. [Design of acetylcholinesterase inhibitor for Alzheimer's disease therapy: from multi-binding site inhibitors to multi-target directed ligands].
Yang WC; Sun Q; Yu NX; Zhu XL; Yang GF
Yao Xue Xue Bao; 2012 Mar; 47(3):313-21. PubMed ID: 22645754
[TBL] [Abstract][Full Text] [Related]
15. Multipotent AChE and BACE-1 inhibitors for the treatment of Alzheimer's disease: Design, synthesis and bio-analysis of 7-amino-1,4-dihydro-2H-isoquilin-3-one derivates.
Zhao XJ; Gong DM; Jiang YR; Guo D; Zhu Y; Deng YC
Eur J Med Chem; 2017 Sep; 138():738-747. PubMed ID: 28728106
[TBL] [Abstract][Full Text] [Related]
16. Investigation of naphthofuran moiety as potential dual inhibitor against BACE-1 and GSK-3β: molecular dynamics simulations, binding energy, and network analysis to identify first-in-class dual inhibitors against Alzheimer's disease.
Kumar A; Srivastava G; Srivastava S; Verma S; Negi AS; Sharma A
J Mol Model; 2017 Aug; 23(8):239. PubMed ID: 28741112
[TBL] [Abstract][Full Text] [Related]
17. In silico repurposing of antipsychotic drugs for Alzheimer's disease.
Kumar S; Chowdhury S; Kumar S
BMC Neurosci; 2017 Oct; 18(1):76. PubMed ID: 29078760
[TBL] [Abstract][Full Text] [Related]
18. Docking, molecular dynamics, binding energy-MM-PBSA studies of naphthofuran derivatives to identify potential dual inhibitors against BACE-1 and GSK-3β.
Kumar A; Srivastava G; Negi AS; Sharma A
J Biomol Struct Dyn; 2019 Feb; 37(2):275-290. PubMed ID: 29310523
[TBL] [Abstract][Full Text] [Related]
19. New neurogenic lipoic-based hybrids as innovative Alzheimer's drugs with σ-1 agonism and β-secretase inhibition.
Estrada M; Pérez C; Soriano E; Laurini E; Romano M; Pricl S; Morales-García JA; Pérez-Castillo A; Rodríguez-Franco MI
Future Med Chem; 2016 Jul; 8(11):1191-207. PubMed ID: 27402296
[TBL] [Abstract][Full Text] [Related]
20. Multitarget drug discovery for Alzheimer's disease: triazinones as BACE-1 and GSK-3β inhibitors.
Prati F; De Simone A; Bisignano P; Armirotti A; Summa M; Pizzirani D; Scarpelli R; Perez DI; Andrisano V; Perez-Castillo A; Monti B; Massenzio F; Polito L; Racchi M; Favia AD; Bottegoni G; Martinez A; Bolognesi ML; Cavalli A
Angew Chem Int Ed Engl; 2015 Jan; 54(5):1578-82. PubMed ID: 25504761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
